Connect Biopharma Holdings Ltd 8-K

What Happened
Connect Biopharma Holdings Ltd (CNTB) filed an 8‑K on April 23, 2026, and issued a press release reporting that the independent Data Monitoring Committee (DMC) completed the pre‑specified interim efficacy analysis for the Phase 2 Seabreeze STAT asthma and COPD trials of rademikibart (an anti‑IL‑4Rα antibody). The DMC made no recommendation to change the trials’ sample size, so the studies will continue as planned. The release is included as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: April 23, 2026 (Current Report on Form 8‑K).
• Trials: Phase 2 Seabreeze STAT program evaluating rademikibart in asthma and COPD.
• DMC decision: Completed pre‑specified interim efficacy review and recommended no change in sample size.
• Document: Press release attached as Exhibit 99.1; report signed by David Szekeres, President.

Why It Matters
For investors, the DMC’s decision means the Phase 2 trials are proceeding on the original timetable and enrollment plan — there is no immediate change in trial scale. This is a neutral operational update: it does not itself confirm efficacy or safety outcomes, only that the interim review did not trigger a sample‑size adjustment. The 8‑K also includes standard forward‑looking statement disclosures and points to the company’s SEC filings (including the 2025 Form 10‑K) for additional risk factors.